Ushering in a New Era of Alzheimer Disease Therapy

Eric W Widera^{1

2}, Sharon A Brangman³, Nathaniel A Chin⁴

Affiliations

¹ Department of Medicine, Division of Geriatric Medicine, University of California, San Francisco.
² San Francisco Veterans Affairs Healthcare System, San Francisco, California.
³ Department of Geriatrics, SUNY Upstate Medical University, Syracuse, New York.
⁴ Department of Medicine, Division of Geriatrics, University of Wisconsin Department of Medicine, Madison.

Editorial

Eric W Widera et al. JAMA. 2023.

. 2023 Aug 8;330(6):503-504.

doi: 10.1001/jama.2023.11701.

Eric W Widera^{1

2}, Sharon A Brangman³, Nathaniel A Chin⁴

¹ Department of Medicine, Division of Geriatric Medicine, University of California, San Francisco.
² San Francisco Veterans Affairs Healthcare System, San Francisco, California.
³ Department of Geriatrics, SUNY Upstate Medical University, Syracuse, New York.
⁴ Department of Medicine, Division of Geriatrics, University of Wisconsin Department of Medicine, Madison.

No abstract available

Comment in

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
Rabinovici GD, La Joie R. Rabinovici GD, et al. JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703. JAMA. 2023. PMID: 37459124 No abstract available.
Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
Manly JJ, Deters KD. Manly JJ, et al. JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704. JAMA. 2023. PMID: 37459138 No abstract available.
Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
Rosenthal MB. Rosenthal MB. JAMA. 2023 Aug 8;330(6):505-506. doi: 10.1001/jama.2023.11702. JAMA. 2023. PMID: 37459140 No abstract available.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.